The Parsortix® PC1 Clinical SystemThe first FDA cleared medical device for the capture and harvest of circulating tumor cells (CTCs) from metastatic breast cancer patient blood for subsequent analysis. Find out more
Building a differentiated position in the multi-billion dollar liquid biopsy market
With advancements in genomics and clinical information there has been a paradigm shift from “one drug fits all” towards “precision medicine” – the right drug for the right patient at the right time.
The Parsortix system is easy to use and can be used with whole blood samples, direct from a simple blood test, without any pre-processing of the blood such as red blood cell removal. This makes the process easy and cost effective whilst ensuring unnecessary loss of target cells is minimized. For Research Use Only- Not for use in clinical diagnostic procedures.
Head to our investor centre to find current financial information, our corporate calendar, stock information and corporate governance.